Neoplasms by Site Completed Phase 1 Trials for Nivolumab (DB09035)

IndicationStatusPhase
DBCOND0030096 (Neoplasms by Site)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01629758Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid TumorsTreatment